- IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price
- Shadow Work: How Businesses Are Turning Us All Into Unpaid Laborers
- Boomers' Biggest Retirement Regret? They Didn't Work Longer
- Carnival CEO Aims to Bust the Biggest Myths About the Cruise Industry
- The 10 Poorest States in America
Another Chinese reverse-merger stock, China-Biotics, fails to file its annual report, leading to yet another trading halt.
Like IBM, these companies have stood the test of time and made untold amounts of money for their shareholders over the long haul.
Nucor seemed downright contrarian with its bullish words on steel demand, but some market watchers remain cautious on the metal-making business.
Look for M&A activity to continue to accelerate as companies and private-equity funds take advantage of cheap financing before the debt spigot closes.
The SEC issues a bulletin warning about the dangers of investing in reverse merger stocks -- clearly motivated by the Chinese stock fraud scandal.
International Paper's hostile takeover bid for Temple-Inland shows that deal-hungry manufacturers are racing to pursue M&A before interest rates rise.
Peru votes a leftist presidential candidate into office, and Wall Street sells off mining stocks with Peruvian exposure.
Dry-bulk shippers have found themselves in a world of hurt. How did it happen, and when will it end?
Morgan Stanley's private-equity arm goes contrarian, agreeing to invest $50 million in Yongye International amid a raft of fraud scandals among Chinese small caps.
North American steel prices have declined sharply in recent weeks, making the outlook for second-half earnings that much murkier.